Mirum's LIVMARLI fails Phase 2b EMBARK trial in biliary atresia; primary endpoint not met

Mirum Pharmaceuticals, Inc.

Phase 2b EMBARK trial of LIVMARLI (maralixibat) in biliary atresia did not meet primary or key secondary endpoints.
LIVMARLI was generally well-tolerated with no new safety findings.
Topline results announced on December 18, 2023.

item 8.01

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-297614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.